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A B S T R A C T
Background
Tetanus is a severe disease that can be prevented by vaccination. In developing countries vaccination coverage is not always high, and
cases still occur in developed countries, particularly in elderly people owing to their reduced immuno protection. There are hundreds
of thousands of tetanus cases per year globally. In animal studies, vitamin C has protected against various infections. In a study with
rats, vitamin C protected against the purified tetanus toxin.
Objectives
To assess the prophylactic and therapeutic effect of vitamin C on tetanus.
Search methods
We searched the Cochrane Wounds Group Specialised Register (searched 4 August 2011); Cochrane Infectious Diseases Group
Specialised Register (Searched 24 August 2011); The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane
Library 2011, Issue 3); Ovid MEDLINE (1950 to August Week 2 2011); Ovid MEDLINE (In-Process & Other Non-Indexed
Citations August 18, 2011); and Ovid EMBASE (2009 to 2010 Week 50) and the reference lists of relevant reviews and monographs.
Selection criteria
Controlled trials of vitamin C as a prevention or treatment for tetanus, whether or not these were placebo controlled, in any language,
published or unpublished. Two authors independently made inclusion decisions.
Data collection and analysis
Both review authors independently extracted data from trial reports and assessed methodological quality. We calculated the relative risk
of death by using the RevMan computer program and odds ratio by using the StatXact computer program.
Main results
One single trial was eligible for inclusion. This non-randomised, controlled, unblinded trial undertaken in Bangladesh involved 117
tetanus patients. Vitamin C at a dosage of 1 g/day was administered intravenously alongside conventional treatment. At recruitment,
the participants were stratified into two age groups and the results were reported by age. In the children aged 1 to 12 years (n = 62),
vitamin C treatment was associated with a 100% reduction in tetanus mortality (95% CI from -100% to -94%). In people aged 13 to
30 years (n = 55), vitamin C treatment was associated with a 45% reduction in tetanus mortality (95% CI from -69% to -5%).
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Authors’ conclusions
A single, non-randomised, poorly reported trial of vitamin C as a treatment for tetanus suggests a considerable reduction in mortality.
However, concerns about trial quality mean that this result must be interpreted with caution and that vitamin C cannot be recommended
as a treatment for tetanus on the basis of this evidence. New trials should be carried out to examine the effect of vitamin C on tetanus
treatment.
P L A I N L A N G U A G E S U M M A R Y
Vitamin C for preventing and treating tetanus
Tetanus is a disease caused by tetanus toxin, which is produced by the bacterium Clostridium tetani. This bacterium typically infects
penetrating wounds contaminated by foreign material such as soil. In developing countries, poor hygiene after childbirth may cause
tetanus in newborn babies. Even though vaccination has dramatically decreased the burden of tetanus, there are still hundreds of
thousands of cases per year globally. We found one controlled trial that examined whether one gram per day of intravenous vitamin C
would help in the treatment of tetanus patients. Vitamin C was used alongside standard treatments for tetanus. Intravenous vitamin C
reduced the mortality of children aged between 1 and 12 with tetanus by 100% and that of 13 to 30 year old patients by 45%. The
trial was not properly conducted and caution is required in the interpretation of the findings. Vitamin C cannot be recommended as a
treatment for tetanus on the basis of this single study. Further investigation of the role of vitamin C in tetanus treatment is warranted.
B A C K G R O U N D
Description of the condition
’Tetanus’ denotes a disease caused by tetanus toxin (tetanospas-
min), a protein that is produced by the anaerobic bacterium
Clostridium tetani. Although the pathological definition of tetanus
is based on the specified bacterium and its toxin, the diagnosis
is made clinically. The clinical picture is dominated by muscle
spasms and rigidity. Often the first sign is rigidity of the jaw mus-
cles, followed by stiffness of the neck, difficulty in swallowing,
and rigidity of the abdominal muscles. Other symptoms include
elevated temperature, raised blood pressure, and an episodically
rapid heart rate. Tetanus may lead to complications such as frac-
tures of the spine or long bones because of contractions and con-
vulsions, and to pulmonary embolism, bed sores and nosocomial
infections due to prolonged hospitalisation. The current treat-
ment of tetanus consists, for example, of surgical debridement of
the wound and antibiotic therapy (metronidazole) to remove the
source of infection, tetanus immune globulin to neutralize circu-
lating toxin, and benzodiazepine for sedation and muscle relax-
ation (Bleck 2005; CDC 2009; Cook 2001; Farrar 2000; Rhee
2005; Thwaites 2006a; WHO 2009).
Tetanus is typically caused by anaerobic bacterial growth in a con-
taminated penetrating wound. Vaccination against tetanus has
dramatically reduced the incidence of the disease in developed
countries, but infrequent cases occur, particularly in elderly people
owing to reduced immuno protection (Gergen 1995). Neverthe-
less, hundreds of thousands of tetanus cases per year occur globally
(Thwaites 2003).
In developing countries, neonatal tetanus causes over 100,000 in-
fant deaths per year, due largely to poor umbilical hygiene after
childbirth. According to the World Health Organization (WHO),
Somalia had the highest rate in 1999, with 16.5 neonatal tetanus
deaths per 1000 live births (WHO 2000). Vaccination of moth-
ers would prevent the majority of these cases and the WHO has
campaigned to increase the coverage of vaccination in develop-
ing countries (Demicheli 2005; Roper 2007; WHO 2000; WHO
2009).
Although the molecular mechanisms of tetanus toxin in the initi-
ation of pathogenesis are well known, the later stages of the patho-
logical cascade are inadequately understood. There is evidence in-
dicating that disturbances in autonomic control, with sympathetic
overactivity (e.g. elevated blood pressure, rapid heart rate) could
play a crucial role in the pathophysiology of severe tetanus cases
(Cook 2001; CDC 2009; Daher 1997; Wasay 2005). Recently,
Thwaites 2006b reported data supporting the possible role of cat-
echolamines (stress hormones) in tetanus. The concentrations of
epinephrine and norepinephrine were much higher in tetanus pa-
tients than in other critically ill patients and, amongst the tetanus
patients, the concentrations were higher in those who had more
severe forms of tetanus.
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Description of the intervention
Vitamin C was identified in the 1930s in the search for the sub-
stance deficiencies that cause scurvy. After the identification there
was much interest in its effects on diseases unrelated to scurvy, but
the role of vitamin C on other diseases is still unsettled. Vitamin C
supplementation shortened the duration of colds (Hemilä 2007b)
and prevented pneumonia in three trials with participants under
special circumstances (Hemilä 2007a). Dietary vitamin C intake
modified the effect of vitamin E on the mortality of male smokers
(Hemilä 2009). Although such findings indicate that the effects
of vitamin C are not limited to preventing scurvy, their practical
significance is not clear.
In an early case report, Klenner 1954 described that vitamin C
seemed to be beneficial for an unvaccinated six-year-old boy who
contracted tetanus. However, vitamin C was used in addition to
tetanus antitoxin, penicillin, adrenal cortex extract and Tolserol
(mephenesin, muscle relaxant). Although the boy was cured and
discharged from hospital on the 18th day, the specific role of vi-
tamin C in the curing process cannot be inferred from the report.
Usually vitamin C is administered as tablets, but it can also be
administered intravenously. A recent pharmacokinetic study com-
pared oral and intravenous administration and found substan-
tially higher plasma levels when vitamin C was administered by
intravenous route compared with oral administration (Padayatty
2004). The highest dose used in the pharmacokinetic study, 100
g of vitamin C intravenously given over a few hours, increased
the plasma concentration peak to 15,000 µmol/L, which is over
100 times the plateau level reached by oral administration (Levine
1996; Padayatty 2004).
Vitamin C is safe in high doses. A dose of approximately 10 mg/
day prevents scurvy but, according to the US nutritional recom-
mendations, the ’tolerable upper intake level’ is 2 g/day for adults
(IOM 2000). The basis for this upper limit is the appearance of
diarrhoea, which is, however, a trivial adverse effect that disappears
quickly with a reduction in intake. Several other reviewers have
also concluded that vitamin C is safe in doses ranging to several
grams per day (Hathcock 2005; Hemilä 2006; Rivers 1987).
How the intervention might work
As described above, sympathetic overactivity with elevated levels of
catecholamines may pay a role in the pathophysiology of tetanus.
Vitamin C is involved in the synthesis of norepinephrine, and
the adrenal glands have the highest concentration of this vitamin
in the body (Diliberto 1991; Levine 1985; Patak 2004; Rice
2000). Various infections and purified bacterial toxins lead to the
depletion of vitamin C from the adrenal glands (Hemilä 2006). A
few experimental studies have shown that vitamin C improved the
functions of phagocytes and the proliferation of T-lymphocytes,
indicating that it has a role in the immune system (Hemilä 2006).
In dozens of animal studies, vitamin C increased resistance against
diverse infections and a few purified bacterial toxins (Hemilä
2006). In particular, Dey 1966 reported that five rats administered
twice the minimal lethal dose of tetanus toxin all died, whereas
25 rats administered vitamin C either before or after the toxin all
lived (Hemilä 2006). Vitamin C also reduced mortality in mice
caused by toxins of several Clostridium species (Büller Souto 1939;
Hemilä 2006).
Chakrabarti 1955 reported that tetanus patients had lower plasma
vitamin C levels than healthy people, and tetanus patients who
died had lower levels than those who survived. Furthermore,
tetanus patients had elevated levels of dehydroascorbate, which
is the oxidized form of vitamin C. Such changes in vitamin C
metabolism provide a further rationale to test vitamin C for tetanus
patients.
Although vitamin C affects the immune system, it may be impor-
tant only in particular conditions. For example, it is possible that
variation in dietary vitamin C intake is not crucial in the ordinary
western population because of their relatively high dietary intake
levels, yet vitamin C might be a limiting factor in populations
with low intakes. In the extreme, the prevalence of scurvy (vitamin
C deficiency) was reported to be up to 44% in refugee camps in
Somalia (WHO 1999).
Why it is important to do this review
Tetanus is a severe disease afflicting hundreds of thousands of
people annually and vitamin C is a safe and inexpensive essential
nutrient. The possibility that vitamin C may have an action on
tetanus is therefore worthy of systematic consideration.
Links to the publications cited in this Background section,
for which full text versions are available, can be found at:
www.ltdk.helsinki.fi/users/hemila/CT.
O B J E C T I V E S
To determine the effects of vitamin C supplementation for:
(1) preventing the development of tetanus in vaccinated and un-
vaccinated individuals;
(2) treating patients with a diagnosis of tetanus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Controlled clinical trials, both randomised and non-randomised.
The review includes studies with and without placebo control
since, firstly, it is unlikely that being aware of taking or not tak-
ing vitamin C would influence such a severe disease as tetanus;
and secondly, a recent meta-analysis of trials comparing a placebo
group with a no-treatment group found no evidence of a placebo
effect on binary outcomes, although placebo did have an effect
on pain measured as a continuous outcome (Hrobjartsson 2001;
Hrobjartsson 2010).
Types of participants
We included studies involving people of any age and sex, either
vaccinated or unvaccinated (prevention) or who had a diagnosed
condition of tetanus (treatment). In this review we include both
neonatal tetanus and tetanus cases occurring after the neonatal
period.
Types of interventions
Studies in which treatment with vitamin C was the only systematic
difference between the treatment arms were eligible for inclusion.
We included studies comparing outcomes after the administration
of vitamin C (ascorbic acid or its salts or other derivatives; orally
or intravenously) with the administration of no or a lower dose of
vitamin C. We did not apply restrictions on the dosage and fre-
quency of administration of vitamin C, and we considered treat-
ment trials using a single dose and trials in which vitamin C was
administered with other treatments, provided co-interventions did
not differ between the treatment arms. We regarded ’prevention
trials’ as those in which regular vitamin C was administered to
people who did not have tetanus and ’treatment trials’ as those in
which vitamin C was administered after the diagnosis of tetanus.
Types of outcome measures




1. Incidence of tetanus.
Treatment trials:
1. Mortality;




2. Duration of hospital stay;
3. Severity of symptoms and complications.
Treatment trials:
1. Severity and occurrence of complications such as fractures
and nosocomial infections.
Search methods for identification of studies
Electronic searches
For an outline of the search methods used in first update of this
review see Appendix 1.
For this second update the following databases and dates are cov-
ered:
• Cochrane Wounds Group Specialised Register (searched 4
August 2011);
• Cochrane Infectious Diseases Group Specialised Register
(searched 24 August 2011);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2011, Issue 3);
• Ovid MEDLINE (1950 to August Week 2 2011);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations August 18, 2011);
• Ovid EMBASE (2009 to 2010 Week 50)
The following strategy was used to search The Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Tetanus explode all trees
#2 tetanus
#3 (#1 OR #2)
#4 MeSH descriptor Ascorbic Acid explode all trees
#5 ascorb* or “vitamin C”
#6 (#4 OR #5)
#7 (#3 AND #6)
The search strategies for Ovid MEDLINE and Ovid EMBASE
can be found in Appendix 2 and Appendix 3 respectively. No
methodological filters were used. No date or language restrictions
were applied.
Searching other resources
Previously, Briggs 1984 carried out extensive literature searches
and published a bibliography containing over 400 references to
papers related to vitamin C and infections, which we checked. We
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also searched the reference lists of all other pertinent reviews and
of the potentially eligible studies identified in our search.
Data collection and analysis
Selection of studies
The first review author searched the literature and both review
authors independently assessed the titles and abstracts to identify
potentially relevant articles. We obtained full versions of all po-
tentially eligible articles, which we scrutinised independently.
Data extraction and management
Both review authors independently extracted pertinent data from
the articles selected. We recorded the following quality features
of the trials on data extraction forms as ’yes’, ’no’, ’unclear’: ran-
domised allocation, allocation concealment, blinding of partici-
pants, blinding of investigator, blinding of outcome assessor, blind
data analysis and intention-to-treat analysis. We also recorded
baseline measurements and percentage dropout during follow up.
For a discussion of these quality items, see Higgins 2011 (chapter
eight).
Assessment of risk of bias in included studies
We did not calculate any quality scores for selected trials be-
cause “quality scores are at best useless and at worst misleading”
(Greenland 1994), and “the use of scales for assessing quality
or risk of bias is explicitly discouraged in Cochrane reviews. ”
(Higgins 2011 sect 8.3.3). Furthermore, even though shortcom-
ings in the design and conduct of trials may lead to erroneous con-
clusions (Higgins 2011 chapter 8), a recent meta-analysis of 276
randomised controlled trials found that double blinding and allo-
cation concealment, two quality measures that are frequently used
in meta-analyses, were not associated with treatment effects (Balk
2002). We agree with the Shapiro 1997 comment that “quality is
best evaluated qualitatively ... the author should give reasons for
judging the quality of any given study as good or bad in transpar-
ent and easily comprehensive language. It is then up to the reader
to decide whether he agrees or disagrees.” Following such reason-
ing, we decided to describe the weaknesses and strengths of trials
explicitly in the ’Risk of bias in included studies’ section.
Measures of treatment effect
We entered the case fatality rate data of the identified Jahan 1984
study to the RevMan 2009 computer program and calculated the
relative risk (RR), presenting the results with 95% confidence in-
tervals (CI). Because a cell of the 2×2 table was empty in one com-
parison and the RevMan algorithm is inappropriate for analysing
such a table, we used the StatXact 2009 software (release 7) to cal-
culate the exact 95% CI for the odds ratio (OR) as an approxima-
tion of RR (Rothman 1998). We also calculated the Fisher exact
test P-value for the comparisons. We used two-tailed P values in
this review.
Unit of analysis issues
The patients in the Jahan 1984 trial were divided into two wards
by vitamin C administration. Although this may cause bias in
treatment, it does not affect the unit of analysis (the individual
patient), because tetanus is not a contagious disease.
Assessment of heterogeneity
We assessed heterogeneity using the I2 statistic (Higgins 2003).
This examines the percentage of total variation across studies that
is due to heterogeneity rather than chance. A value of I2 greater
than about 70% indicates a high level of heterogeneity.
Data synthesis
We did not pool the age groups of the Jahan 1984 trial, because
there was a high level of heterogeneity.
R E S U L T S
Description of studies
See: Characteristics of included studies.
No new eligible trials were identified in the searches carried out for
the first and second updates of this review. From the original search
we found one eligible controlled trial that provided data pertinent
to vitamin C in the treatment of tetanus patients (Jahan 1984),
but we found no trials reporting on the prevention of tetanus with
vitamin C. The main features of the Jahan trial are briefly sum-
marised in the table ’Characteristics of included studies’, but de-
scribed in detail in the following section because the weaknesses
and strengths are crucial when considering the validity of it’s find-
ings. The Jahan 1984 trial was carried out in Bangladesh in the
early 1980s. A total of 117 tetanus patients were admitted to the
Infectious Disease Hospital in Dhaka and divided into two age
groups at recruitment. There were 62 children in the age group 1
to 12 years, and 55 children and adults in the age group 13 to 30
years. The Jahan report is available at www.ltdk.helsinki.fi/users/
hemila/CT.
5Vitamin C for preventing and treating tetanus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Risk of bias in included studies
Jahan 1984 did not describe the allocation method, but the vi-
tamin C and control arms were of the same size: 31 compared
with 31 in the younger age band; and 27 (vitamin C) compared
with 28 (control) in the older participants. Allocation conceal-
ment could not be judged from the report. Patients allocated vita-
min C received 1 g/day intravenously “in addition to conventional
antitetanus therapy which included antitetanus serum, sedatives,
antibiotics and muscle relaxant etc.” (p 25). Participants allocated
to the control arm received conventional antitetanus therapy but
the administration of placebo is not mentioned. No baseline data,
except for the age ranges, are presented for the two trial arms.
There is no description of how tetanus was diagnosed. The au-
thors present results for 117 patients in a table indicating that all
recruited patients were included in the analysis. The trialists did
not state the duration of intervention or their duration of follow-
up, but stated that “patients succumbed to tetanus even three to
four weeks after admission” (p 27).
Thus, the Jahan 1984 trial had two age groups with treatment
and control arms of similar size and administration of vitamin C
was the only systematic difference between them. However, the
methodological description in the Jahan report is minimal. The
role of the methodological shortcomings in the interpretation of
the study results are considered in the ’Discussion’ section.
We were able to contact the first author of the Jahan 1984 trial.
To our query about the methods of the 1984 trial, we received this
reply: “we selected two wards side by side. Patients of one ward
were under treatment with vitamin C in addition to conventional
treatments. In another ward patients were enrolled as a control
group and got only the conventional treatment (without vitamin
C). Age groups and the number of patients we tried to match
as far as possible. Because we had to take the patients who were
inpatients in the hospital we did not use a placebo. We were not
able to hide the allocations from the physicians at that stage. Follow
up of the patients was until they were discharged as fit persons or
died. Diagnosis of the disease was done by a physician specialised




We did not identify any trials describing the effects of vitamin C
as a prevention for tetanus.
Treating tetanus
Effect on case fatality rate
We identified one controlled trial that examined the effects of 1 g/
day vitamin C given intravenously for patients with tetanus (Jahan
1984). At recruitment, the participants were stratified into two
age groups and the results were reported by the age group.
Ages 1 to 12 years: vitamin C significantly reduced the case fatality
rate (0/31; 0% mortality) compared with control (23/31; 74%
mortality). According to RevMan, the relative risk (RR) of death
(vitamin C relative to control) was 0.02 (95% CI from 0.00 to
0.34). Analysis 1.1; subgroup 1.
Ages 13 to 30 years: vitamin C significantly reduced the case fa-
tality rate (10/27; 37% mortality) compared with control (19/28;
68% mortality). The RR of death was 0.55 (95% CI from 0.31
to 0.95). Analysis 1.1; subgroup 2.
The above RR and CI values were calculated using the RevMan
program. However, there were no deaths in the younger tetanus
patients administered vitamin C and in such a case RevMan adds
0.5 to each cell of the 2×2 table (Higgins 2011 sect 9.4.4), which
leads to an erroneous estimate and P-value. Therefore, we used
the StatXact program to calculate the exact CI of the odds ratio
(OR) for the young patients: OR of death was 0.00 (95% CI from
0.00 to 0.06). The Fisher’s exact test, which is valid for tables with
an empty cell, gives P=3×10−10 for the comparison of vitamin C
and control arms of the young patients, whereas the RevMan gives
P=0.006. For the older tetanus patients, the RevMan algorithm
and the Fisher exact test give the same P-value as expected because
there were a reasonable number of deaths in both study arms.
Heterogeneity between the subgroups
We found strong evidence of heterogeneity in the effect of vitamin
C between the young and old patients. The RevMan gives the I
2 value 90% indicating a high level of heterogeneity. Vitamin C
had a greater effect in the younger participants. The authors of the
Jahan 1984 trial reported the results of the age groups separately
and they did not combine the results. We did not pool the age
strata because of the high level of heterogeneity.
Sensitivity analysis based on the rejection of trials with lower
methodological quality was not possible because we identified only
one trial.
D I S C U S S I O N
Quality of the evidence
We identified one trial that examined the therapeutic effect of vi-
tamin C on the mortality of people with tetanus(Jahan 1984). In
the first update of this review,no new trials were identified. The
Jahan 1984 trial reported a highly significant benefit associated
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with intravenous vitamin C on the case fatality rate of tetanus pa-
tients. The methods used in the Jahan trial were, however, unsatis-
factory and superficially described. Here we will consider whether
potential biases could explain the differences reported in the case
fatality rate between the vitamin C and control arms.
Jahan 1984did not state an explicit case definition for tetanus.
Although this is a shortcoming in the report, it does not seem
reasonable to assume that tetanus was improperly diagnosed in an
infectious diseases hospital in a country that had a high incidence
of this disease (currently the incidence is lower). Furthermore, the
trial author described in a personal letter that the diagnosis was by
a “physician specialised in infectious diseases”.
Selection bias operates when there are systematic differences be-
tween comparison groups at baseline. Adequate randomisation
with allocation concealment guards against it. No data were pre-
sented by Jahan 1984 to allow us to judge whether the allocation
process resulted in balanced allocation between treatment groups
for prognostic factors. This trial was not randomised and there
is a risk of selection bias (the ward a patient was allocated to de-
termined whether they received vitamin C). However, it is highly
unlikely that potential baseline differences could lead to such great
difference in mortality between the study arms as reported for the
younger patients.
Performance bias operates when there are systematic differences
in the care provided apart from the intervention being evalu-
ated. Jahan 1984 stated that both vitamin C and control arms
received “conventional antitetanus therapy which included antite-
tanus serum, sedatives, antibiotics and muscle relaxant etc.”, so the
administration of vitamin C was the only systematic difference be-
tween the trial arms. However, the vitamin C and control patients
were treated in different wards, which is unsatisfactory because
aspects of treatment could be somewhat different between the two
wards. Placebo was not used in Jahan 1984, but a recent meta-anal-
ysis found that, in trials examining various topics, placebo arms
did not differ from no-treatment arms if the outcome was binary;
e.g. mortality (Hrobjartsson 2010). Thus, the care providers may
have been aware of which arm the patients had been enrolled into,
but it is highly unlikely that such knowledge would have altered
treatment to such an extent that it could explain the difference
in mortality between the study arms as reported for the younger
patients in Jahan 1984.
Attrition bias operates when there are large numbers of people
who withdraw from the study or when the rates of withdrawal
are different between treatment arms. Attrition bias is unlikely in
Jahan 1984, since all patients allocated were followed up and anal-
ysed. Furthermore, in a personal letter, the trial author confirmed
that all patients were followed up “until they were discharged as
fit persons or died”.
Detection bias operates when there are systematic differences in
the ways outcomes were assessed between treatment groups and is
more likely to occur when there is no blinded outcome assessment
and when the outcome is subjective. It is unlikely, however, that
detection bias is operating in Jahan 1984since the outcome was
mortality which is not a subjective outcome. There is minimal
possibility of bias in detecting mortality in a hospital.
Consequently, although the methods of the Jahan 1984 trial are
poorly described and the trial was poorly conducted, the biases
discussed above cannot explain the reported findings. There seems
to be no basis to assume attrition bias or detection bias in the
trial. Possibly there has been selection bias and performance bias
to some degree, but this cannot explain the reported difference in
outcomes among the younger participants. Glasziou 2007 argued
that rate ratios beyond 10 are highly likely to reflect real treatment
effects, even if confounding factors may contribute to the size of the
observed effect. In the younger patients of the Jahan trial, the entire
confidence interval and not just the point estimate is beyond the
ratio of 10. In the older patients of the Jahan trial, the confidence
interval of the vitamin C effect is close to the control group level,
and therefore the results are not robust to the possibility of selection
and performance biases. Nevertheless, the findings in the older
patients are consistent with the findings in the younger patients.
Finally, the existence of a single positive study might be explained
by publication bias, meaning that researchers tend to report studies
with ’positive’ results but not those with ’negative’ results. With
this reasoning, it is possible that Jahan 1984 was published just
because vitamin C appeared beneficial (but simply by chance),
whereas several trials might remain unpublished because of their
negative results. Publication bias may explain findings that are
close to statistical significance, but it is an unlikely explanation
for highly statistically significant findings such as those of the
younger patients in the Jahan 1984 trial. Furthermore, it would
seem incomprehensible that publication bias would generate the
highly significant difference between the age groups. Therefore we
do not consider that publication bias is relevant in this case.
Applicability of the evidence
The Jahan 1984 trial is methodologically unsatisfactory and great
caution is required in the interpretation of the results; also because
there are no other trials giving independent support to the findings.
Nevertheless, a few animal studies are consistent with the concept
that vitamin C might protect against clostridial toxins (Büller
Souto 1939; Dey 1966).
In Jahan 1984, vitamin C was used over and above treatments that
are still used for treating tetanus patients. In this respect, the trial
is not outdated.
When considering extrapolation of the findings of vitamin C tri-
als, an issue of particular importance is the level of dietary vita-
min C intake. A different outcome between the vitamin C and
control arms may result from a particularly low dietary intake in
the control arm (’marginal vitamin C deficiency’) or from the high
dose supplementation in the vitamin C arm. In the former case, a
small dosage of supplement may produce a similar effect, whereas
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in the latter case the high dose is necessary. As reference levels:
scurvy may be caused by vitamin C intake of less than 10 mg/day,
whereas the mean vitamin C intake, for example, in the USA is
about 100 mg/day (IOM 2000).
If the biological basis for the results in Jahan 1984 was the treat-
ment of marginal deficiency, this would not provide an explana-
tion for the significant heterogeneity between the age groups, as
the dose is so high that it would cure marginal deficiency in both
age groups. Thus, it is possible that the high dose, 1 g/day, was
essential for the results. Furthermore, the benefit of vitamin C was
significantly greater for the younger patients (1 to 12 years), who
weigh on average less than the older patients (13 to 30 years). Thus
the heterogeneity might have resulted from dose dependency be-
cause the dose per weight is higher in the younger patients. How-
ever, there are numerous other differences between the younger
and older patients, and some of them might explain the hetero-
geneity as well. Therefore, dose dependency should be considered
as only one of the possible reasons for the high level of heterogene-
ity between the age groups.
In the Jahan 1984 trial, vitamin C was administered intravenously
which increases plasma level substantially more than oral admin-
istration (Padayatty 2004). Therefore, the same dose of vitamin C
as tablets might not have similar effects.
Safety of vitamin C
In the Jahan 1984 trial, no adverse effects related to the intravenous
1 g/day vitamin C administration were mentioned.
There is evidence indicating that high dose vitamin C is usually safe
when administered intravenously. A matched case control study
of cancer patients found that 10 g/day vitamin C by intravenous
infusion for 10 days and orally thereafter was associated with a
longer survival time which indicates the absence of harmful effects
with such a dosage (Cameron 1976). High intravenous vitamin
C doses, up to 65 g twice per week for 10 months, have also
been reported for cancer patients (Padayatty 2006). A case report
described the use of intravenous vitamin C doses at levels up to 28
g/day for a six-year-old boy with tetanus (Klenner 1954). There
are few reports of severe harm caused by high-dose vitamin C
administration. Furthermore, the death of a 68-year-old African
American man was not attributed to the intravenous injection
of 80 grams of vitamin C on two consecutive days per se, but
to his coincident glucose-6-phosphate dehydrogenase deficiency
(Campbell 1975). Consequently, there seems to be no concern
about the safety of the intravenous dosage level, 1 g/day, used in
Jahan 1984.
Cathcart 1981 stated that patients with severe infections can take
over 30 g/day of vitamin C orally without suffering from diar-
rhoea, whereas healthy people can take only 4 to 10 g/day. This
difference in tolerable doses may be caused by the changes in
vitamin C metabolism because of severe infections (Chakrabarti
1955; Hemilä 2006). Thus, it is possible that the range of safe
doses extends to higher levels in people who have severe infections
compared with healthy people. Nevertheless, in a pharmacoki-
netic study, no adverse effects were reported with the administra-
tion of up to 100 g of vitamin C intravenously to healthy people
(Padayatty 2004).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A single poor quality and poorly reported controlled trial found
that 1 g/day intravenous vitamin C significantly reduced death
rates in people with tetanus. The poor quality of this trial means
that routine vitamin C use cannot be recommended on the basis
of this trial alone. There were no evaluations of vitamin C as a
prevention for tetanus.
Implications for research
Treatment trials: more research is needed into the effect of vitamin
C on mortality of tetanus patients. Vitamin C should be studied
as an addition to conventional therapy.
Prevention trials: because of vaccination, tetanus is nearly non-ex-
istent in children and middle-aged people in the developed world.
Although vaccination should be a priority in developing countries,
the prophylactic effects of vitamin C supplementation might be
investigated in populations with a high incidence of tetanus.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Jahan 1984
Methods Non randomised; allocation method not described.
Vitamin C and control participants treated in separate wards.
No placebo; no blinding.
Duration up to 4 weeks.
Participants 117 tetanus patients admitted to the Infectious Disease Hospital, Dhaka, Bangladesh.
Age group 1 to 12 years: 31 vitamin C, 31 control.
Age group 13 to 30 years: 27 vitamin C, 28 control.
Interventions Vitamin C intravenously 1 g/day vs. no vitamin C. Both groups received standard treatment
Outcomes Case fatality rate.
Notes Poorly described trial (see Risk of bias in included studies).
Additional information was received from the first author, Professor Jahan
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Inadequate
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin C vs control




participants Statistical method Effect size
1 Case fatality rate 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 aged 1 to 12 years 1 62 Risk Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.34]
1.2 aged 13 to 30 years 1 55 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.31, 0.95]
Analysis 1.1. Comparison 1 Vitamin C vs control, Outcome 1 Case fatality rate.
Review: Vitamin C for preventing and treating tetanus
Comparison: 1 Vitamin C vs control
Outcome: 1 Case fatality rate
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 aged 1 to 12 years
Jahan 1984 0/31 23/31 100.0 % 0.02 [ 0.00, 0.34 ]
Subtotal (95% CI) 31 31 100.0 % 0.02 [ 0.00, 0.34 ]
Total events: 0 (Vitamin C), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0062)
2 aged 13 to 30 years
Jahan 1984 10/27 19/28 100.0 % 0.55 [ 0.31, 0.95 ]
Subtotal (95% CI) 27 28 100.0 % 0.55 [ 0.31, 0.95 ]
Total events: 10 (Vitamin C), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
0.001 0.01 0.1 1 10 100 1000
Favours vitamin C Favours control
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A P P E N D I C E S
Appendix 1. Search methods for the first review update (2009)
Electronic searches
For this first update we searched the following electronic databases:
Cochrane Wounds Group Specialised Register (Searched 11/11/09);
Cochrane Infectious Diseases Group Specialised Register (Searched 23/11/09);
The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library 2008 Issue 4;
Ovid MEDLINE - 1950 to 2009 Nov Week 1;
Ovid EMBASE - 2005 to 2009 Week 45.
The following strategy was used to search The Cochrane Central Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Tetanus explode all trees
#2 tetanus
#3 (#1 OR #2)
#4 MeSH descriptor Ascorbic Acid explode all trees
#5 ascorb* or “vitamin C”
#6 (#4 OR #5)
#7 (#3 AND #6)
The search strategies for Ovid MEDLINE and Ovid EMBASE can be found in Appendix 2 and Appendix 3 respectively. No method-
ological filters were used. No date or language restrictions were applied.
Searching other resources
We searched the review by Briggs 1984 and the books by Levy 2002 and Stone 1972, which list extensively the older literature related
to vitamin C and infections. We also searched the reference lists of all other pertinent reviews and of the potentially eligible studies
identified in our search.
Appendix 2. Ovid MEDLINE search strategy
1 exp Tetanus/
2 exp Tetanus Toxin/
3 exp Tetanus Toxoid/
4 tetanus.mp.
5 or/1-4
6 exp Ascorbic Acid/
7 ascorb$.mp.
8 (vitamin$ adj5 C).mp.
9 or/6-8
10 5 and 9
Appendix 3. Ovid EMBASE search strategy
1 exp Tetanus/
2 exp Tetanus Toxin/
3 exp Tetanus Toxoid/
4 tetanus.mp.
5 or/1-4
6 exp Ascorbic Acid/
7 ascorb$.mp.
8 (vitamin$ adj5 C).mp.
9 or/6-8
10 5 and 9
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W H A T ’ S N E W
Last assessed as up-to-date: 25 August 2011.
Date Event Description
26 August 2011 New search has been performed Second update, new search, no new trials identified, conclusions not changed
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 2, 2008
Date Event Description
19 November 2009 New search has been performed New search, no new trials identified, conclusions not
changed
11 November 2008 Amended Contact details updated
6 August 2008 Amended Converted to new review format
15 January 2008 New citation required and conclusions have changed Substantive amendment
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MeSH check words
Adolescent; Adult; Child; Child, Preschool; Humans; Infant
16Vitamin C for preventing and treating tetanus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
